Lyra Therapeutics (LYRA) Operating Expenses (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Operating Expenses of $7.1 million in Q4 2025, up 13.78% on a QoQ basis from $6.3 million in Q3 2025, and down 38.67% YoY from $11.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Operating Expenses (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Operating Expenses for 7 consecutive years, with $7.1 million the latest figure, recorded in Q4 2025.
- Operating Expenses for Q4 2025 came in at $7.1 million, down 38.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.4 million (down 67.9% YoY), and the FY2025 annual result was $31.4 million, down 67.9% from the prior year.
- Operating Expenses for Q4 2025 stood at $7.1 million, up from $6.3 million in the prior quarter.
- The five-year high for Operating Expenses was $49.6 million in Q2 2024, with the low at $6.3 million in Q3 2025.
- A 5-year average of $15.0 million and a median of $13.3 million in 2021 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses soared 192.27% in 2024 and tumbled 81.83% in 2025, its largest moves.
- Lyra Therapeutics' Operating Expenses stood at $13.9 million in 2021, then advanced by 9.04% to $15.2 million in 2022, then grew by 9.61% to $16.6 million in 2023, then slumped by 30.11% to $11.6 million in 2024, then sank by 38.67% to $7.1 million in 2025.
- The last three Operating Expenses figures came in at $7.1 million (Q4 2025), $6.3 million (Q3 2025), and $9.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 541.02 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.13 Mn |
| Sep 30, 2025 | 6.26 Mn |
| Jun 30, 2025 | 9.01 Mn |
| Mar 31, 2025 | 9.02 Mn |
| Dec 31, 2024 | 11.62 Mn |
| Sep 30, 2024 | 12.64 Mn |
| Jun 30, 2024 | 49.57 Mn |
| Mar 31, 2024 | 24.06 Mn |
| Dec 31, 2023 | 16.62 Mn |
| Sep 30, 2023 | 17.37 Mn |
| Jun 30, 2023 | 16.96 Mn |
| Mar 31, 2023 | 17.72 Mn |
| Dec 31, 2022 | 15.17 Mn |
| Sep 30, 2022 | 15.19 Mn |
| Jun 30, 2022 | 14.93 Mn |
| Mar 31, 2022 | 12.39 Mn |
| Dec 31, 2021 | 13.91 Mn |
| Sep 30, 2021 | 11.10 Mn |
| Jun 30, 2021 | 11.07 Mn |
| Mar 31, 2021 | 7.83 Mn |